PMID- 25652751
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 69
IP  - 6
DP  - 2015 Jun
TI  - A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly 
      patients with type 2 diabetes mellitus.
PG  - 626-31
LID - 10.1111/ijcp.12607 [doi]
AB  - INTRODUCTION: In the USA, 45% of patients with type 2 diabetes mellitus (T2DM) 
      are elderly (>/= 65 years old). In general, use of sulfonylurea increases with 
      patient age as does the associated risk for hypoglycaemia, and the consequences 
      of hypoglycaemia can be more pronounced in elderly patients. Sitagliptin, a DPP-4 
      inhibitor, improves glycaemic control in adult patients of all ages with T2DM, 
      with a low risk of hypoglycaemia when used alone or in combination with other 
      antidiabetic agents that are not generally associated with hypoglycaemia when 
      used independently. METHODS: In a post hoc analysis, pooled data from elderly 
      patients who participated in one of three double-blind studies comparing the 
      effects of therapy with sitagliptin (100 mg/day) vs. sulfonylurea (in titrated 
      doses) were analysed for changes from baseline in HbA1c, fasting plasma glucose 
      (FPG), and body weight and for the incidence of reported symptomatic 
      hypoglycaemia. In these studies, patients on diet alone or metformin were 
      randomised to sitagliptin or glipizide for 104 weeks (studies 1 and 2) or 
      glimepiride for 30 weeks (study 3). The analysis included 372 elderly patients 
      who completed a trial through 25 or 30 weeks. RESULTS: Both HbA1c and FPG 
      decreased from baseline with each treatment, with no statistically significant 
      differences between treatments. A significantly lower incidence of reported 
      hypoglycaemia was observed with sitagliptin compared with sulfonylurea (6.2% vs. 
      27.8%; p < 0.001). Body weight decreased significantly with sitagliptin but not 
      with sulfonylurea. Significantly more patients on sitagliptin than on 
      sulfonylureas achieved a composite end-point of >0.5% HbA1c reduction with no 
      reported hypoglycaemia or increase in body weight (44.1% vs. 16.0%; p < 0.001). 
      CONCLUSION: In this analysis of elderly patients with T2DM, compared with 
      sulfonylurea, sitagliptin provided similar glycaemic efficacy with less 
      hypoglycaemia and with body weight loss.
CI  - (c) 2015 John Wiley & Sons Ltd.
FAU - Shankar, R R
AU  - Shankar RR
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - Xu, L
AU  - Xu L
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - Golm, G T
AU  - Golm GT
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - O'Neill, E A
AU  - O'Neill EA
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - Goldstein, B J
AU  - Goldstein BJ
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - Kaufman, K D
AU  - Kaufman KD
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
FAU - Engel, S S
AU  - Engel SS
AD  - Merck & Co., Inc., Whitehouse Station, NJ, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150204
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Sitagliptin Phosphate/*therapeutic use
MH  - Sulfonylurea Compounds/*therapeutic use
EDAT- 2015/02/06 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/02/06 06:00
PHST- 2015/02/06 06:00 [entrez]
PHST- 2015/02/06 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1111/ijcp.12607 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2015 Jun;69(6):626-31. doi: 10.1111/ijcp.12607. Epub 2015 Feb 
      4.